Oxaliplatin is mainly used clinically in gastrointestinal tract tumors, such as colorectal cancer and gastric cancer. Studies have shown that oxaliplatin is also effective in non-small cell lung cancer, breast cancer, and head and neck tumors. The dosing is 130mg/m2 IV over two hours, and in clinical practice it is mostly used up to 200mg which is four doses. It is given on the first day and repeated every 21 days, usually used for 6-8 cycles. Oxaliplatin adverse reactions are: 1, neurotoxicity, manifested as sensory dullness and abnormal sensation, will be aggravated by cold, so in the clinic to instruct patients not to gargle with cold water, do not wash their hands with cold water; 2, gastrointestinal reactions, the incidence of nausea and vomiting is relatively high, in the drug process with the joint application of antiemetic drugs; 3, hematological toxicity, manifested as bone marrow suppression, mostly mild to moderate; 4, other Rarely, there are adverse reactions such as elevated transaminases.